American Mart Corporation (AMRT) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
American Mart Corporation (AMRT) trades at $110.00 with AI Score 46/100 (Grade C). Amryt Pharma plc is a biopharmaceutical company focused on developing and commercializing novel therapeutics for rare and orphan diseases. Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for AMRT: AMRT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AMRT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AMRT: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
American Mart Corporation (AMRT) Healthcare & Pipeline Overview
Amryt Pharma plc, acquired by Chiesi Farmaceutici S.p.A. in 2023, specializes in developing and commercializing treatments for rare and orphan diseases, particularly in dermatology. Its key products target unmet needs in epidermolysis bullosa and related conditions, serving a niche market within the broader pharmaceutical sector.
What Is the Investment Thesis for AMRT?
Amryt Pharma, prior to its acquisition, presented a compelling investment thesis centered on its focus on rare diseases with significant unmet medical needs. Key value drivers included the commercial success of Filsuvez in treating EB, a market with limited therapeutic options. Revenue growth was expected to be driven by increased market penetration of Filsuvez and Lomitapide, as well as potential label expansions and new product launches. The company's strong intellectual property portfolio and experienced management team further supported its growth prospects. However, potential risks included regulatory hurdles, competition from emerging therapies, and the inherent challenges of developing and commercializing drugs for rare diseases. The acquisition by Chiesi Farmaceutici validated Amryt's strategic focus and the value of its rare disease portfolio.
Based on FMP financials and quantitative analysis
AMRT Key Highlights
Filsuvez (birch bark extract) was approved for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB).
- Lomitapide (Juxtapid/Lojuxta) was commercialized for homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder.
- Amryt had a commercial presence in North America, Europe, and other international markets.
- The company focused on acquiring, developing, and commercializing novel treatments for rare and orphan diseases.
- Amryt was acquired by Chiesi Farmaceutici S.p.A. in 2023, integrating its rare disease portfolio into Chiesi's operations.
Who Are AMRT's Competitors?
AMRT is benchmarked below against 7 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | $67.61 | +2.36% | $138B | 90 |
| VRTX Vertex Pharmaceuticals Incorporated | $552.06 | +4.52% | $140B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ESALY Eisai Co., Ltd. | $61.51 | -2.11% | $17.6B | 57 |
| FPHAX Fidelity Select Pharmaceuticals | $37.06 | +6.49% | $1.33B | 47 |
| ELAT Elanco Animal Health Inc | $21.32 | +1.04% | 50 | |
| CORI Corium International, Inc. | $12.68 | +0.00% | 44 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AMRT's Key Strengths?
Focus on rare diseases with high unmet medical needs.
- Approved products with established market presence.
- Strong intellectual property protection.
- Experienced management team.
What Are AMRT's Weaknesses?
Reliance on a limited number of products.
- High development costs and regulatory risks.
- Competition from other companies in the rare disease market.
- Dependence on third-party manufacturers and suppliers.
What Could Drive AMRT Stock Higher?
Potential for label expansions for Filsuvez in new indications.
- Continued commercialization and market penetration of Filsuvez and Lomitapide.
- Integration of Amryt's assets and expertise into Chiesi's rare disease portfolio.
What Are the Key Risks for AMRT?
Regulatory setbacks and delays in obtaining approvals for new products.
- Competition from emerging therapies and biosimilars.
- Dependence on third-party manufacturers and suppliers.
- Changes in reimbursement policies and pricing pressures.
What Are the Growth Opportunities for AMRT?
- Expansion of Filsuvez into new markets: Filsuvez, approved for EB, has the potential for further geographic expansion, particularly in emerging markets where access to advanced wound care is limited. The global wound care market is projected to reach $22 billion by 2028, offering a significant opportunity for Filsuvez to capture additional market share. This expansion depends on regulatory approvals and successful commercialization strategies in each new region.
- Development of new formulations and indications for existing products: Amryt could explore new formulations of Filsuvez to improve ease of use and patient compliance. Additionally, investigating the potential of Filsuvez in treating other dermatological conditions beyond EB could expand its market reach. Clinical trials would be necessary to support new indications, with timelines varying depending on the complexity of the studies.
- Acquisition of additional rare disease assets: Prior to the acquisition, Amryt had a strategy of acquiring promising rare disease assets to expand its portfolio. This approach could continue under Chiesi, focusing on therapies that complement existing products and address unmet needs in related therapeutic areas. The timeline for acquisitions depends on the availability of suitable targets and the completion of due diligence and negotiations.
- Leveraging Chiesi's global infrastructure for commercialization: Following the acquisition, Amryt's products can benefit from Chiesi's established global commercial infrastructure, including sales and marketing resources, distribution networks, and regulatory expertise. This can accelerate market penetration and increase sales of Filsuvez and Lomitapide in existing and new markets. The impact of this synergy is expected to be realized within the next 2-3 years.
- Advancing research and development pipeline: Continued investment in research and development is crucial for discovering and developing new therapies for rare diseases. Amryt, now integrated with Chiesi, can leverage its scientific expertise and resources to advance its pipeline of preclinical and clinical-stage programs. This includes exploring novel therapeutic targets and developing innovative drug delivery systems. The timeline for bringing new products to market can range from 5-10 years, depending on the stage of development.
What Are AMRT's Competitive Advantages?
- Intellectual property protection for key products, including patents and market exclusivity.
- Regulatory exclusivity for orphan drugs, providing protection from competition.
- Specialized expertise in developing and commercializing therapies for rare diseases.
- Established relationships with patient advocacy groups and key opinion leaders.
- Brand recognition and reputation in the rare disease community.
What Does AMRT Do?
Amryt Pharma plc, prior to its acquisition by Chiesi Farmaceutici S.p.A. in 2023, was a global biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare and orphan diseases. The company focused primarily on addressing unmet medical needs in patients with rare dermatological conditions, with a strong emphasis on epidermolysis bullosa (EB). Amryt's origins trace back to its commitment to providing innovative therapies for underserved patient populations. Over the years, Amryt built a portfolio of products designed to improve the quality of life for individuals affected by debilitating rare diseases. The company's flagship product was Filsuvez, a birch bark extract ointment approved for the treatment of wounds associated with EB. Additionally, Amryt commercialized Lomitapide (marketed as Juxtapid in the US and Lojuxta in Europe) for homozygous familial hypercholesterolemia (HoFH). Amryt operated globally, with a commercial presence in North America, Europe, and other international markets. The company differentiated itself through its focus on rare diseases, its commitment to patient advocacy, and its strategic approach to acquiring and developing promising therapeutic candidates. Following its acquisition by Chiesi Farmaceutici, Amryt's assets and expertise have been integrated into Chiesi's rare disease portfolio, further strengthening Chiesi's position in the global rare disease market.
What Products and Services Does AMRT Offer?
- Develop and commercialize treatments for rare and orphan diseases.
- Focus on unmet medical needs in dermatology, particularly epidermolysis bullosa (EB).
- Market Filsuvez, a birch bark extract ointment for EB wound treatment.
- Commercialize Lomitapide (Juxtapid/Lojuxta) for homozygous familial hypercholesterolemia (HoFH).
- Operate globally with a commercial presence in North America and Europe.
- Acquire and develop promising therapeutic candidates for rare diseases.
How Does AMRT Make Money?
- Develop or acquire rights to pharmaceutical products targeting rare diseases.
- Conduct clinical trials to demonstrate safety and efficacy.
- Obtain regulatory approvals from agencies like the FDA and EMA.
- Manufacture and market approved products directly or through partners.
- Generate revenue through product sales and licensing agreements.
What Industry Does AMRT Operate In?
Amryt Pharma operated within the biopharmaceutical industry, specifically targeting the rare disease market. This market is characterized by high unmet medical needs, limited treatment options, and often, premium pricing. The rare disease market is growing due to increased awareness, regulatory incentives, and advancements in genetic testing and diagnostics. Competition includes other companies focused on rare diseases, as well as larger pharmaceutical companies with rare disease divisions. Amryt differentiated itself through its focus on specific dermatological conditions like EB and its strategic approach to acquiring and developing promising therapeutic candidates. The acquisition by Chiesi Farmaceutici reflects the increasing consolidation in the rare disease market.
Who Are AMRT's Key Customers?
- Patients with rare diseases, particularly epidermolysis bullosa (EB) and homozygous familial hypercholesterolemia (HoFH).
- Hospitals and clinics that treat patients with these conditions.
- Specialty pharmacies that dispense medications for rare diseases.
- Healthcare providers who prescribe these medications.
Company Profile
American Mart Corporation operates in the Specialty Retail industry within the Consumer Cyclical sector. It is headquartered in Chicago, US. AMRT has traded publicly since 2012.
AMRT Valuation & Market Position
Relative to its peer group, AMRT's quantitative score of 46/100 is below the peer average of 77/100.
AMRT Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in American Mart's future, reflecting a belief in strong upcoming performance.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative product lines and market expansion.
- Analysts are noting improvements in supply chain efficiency, which could enhance profitability moving forward.
- Positive trends in customer engagement and loyalty indicate a strengthening brand presence in a competitive market.
Bear Case
- Concerns have arisen regarding rising operational costs, which could impact margins if not managed effectively.
- Recent negative sentiment in social media discussions reflects worries about potential market saturation in key product categories.
- Some analysts express skepticism about the sustainability of recent growth trends, citing economic uncertainties as a potential headwind.
- Ongoing supply chain disruptions have led to delays, raising questions about the company's ability to meet demand consistently.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
AMRT Latest News
No recent news available for AMRT.
AMRT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AMRT.
Price Targets
Wall Street price target analysis for AMRT.
AMRT MoonshotScore
What does this score mean?
The MoonshotScore rates AMRT 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
AMRT OTC Market Information
AMRT trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
Common Questions About AMRT (Healthcare)
What does the AI Score mean for AMRT?
AMRT holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Amryt Pharma plc is a biopharmaceutical company focused on developing and commercializing novel therapeutics for rare and orphan diseases. The company's portfolio targets unmet medical needs …
What does AMRT do?
Amryt Pharma plc, prior to its acquisition by Chiesi Farmaceutici, was a biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. Its primary focus was on addressing unmet medical needs in dermatology, particularly epidermolysis bullosa (EB). The company marketed Filsuvez for EB wound treatment and Lomitapide for homozygous familial hypercholesterolemia (HoFH).
What do analysts say about AMRT stock?
Prior to its acquisition by Chiesi Farmaceutici, analysts covering Amryt Pharma generally focused on the commercial potential of Filsuvez and Lomitapide, as well as the company's pipeline of rare disease therapies. Key valuation metrics included revenue growth, profitability, and cash flow generation. Analysts also considered the risks associated with regulatory approvals, competition, and market access.
What are the main risks for AMRT?
Prior to its acquisition, Amryt Pharma faced several risks common to the biopharmaceutical industry, including regulatory setbacks, competition from other companies developing rare disease therapies, and the challenges of commercializing products in a fragmented market. The company was also dependent on third-party manufacturers and suppliers, which could disrupt its supply chain.
How does AMRT compare to competitors in its industry?
Amryt Pharma distinguished itself through its focused approach to rare dermatological conditions, particularly epidermolysis bullosa (EB). While larger pharmaceutical companies like Bristol-Myers Squibb and Vertex Pharmaceuticals also have rare disease portfolios, Amryt carved out a niche with its expertise in EB and its commitment to patient advocacy. The company's acquisition by Chiesi Farmaceutici further strengthens its competitive position by leveraging Chiesi's global infrastructure and resources.
What are the key financial metrics investors watch for AMRT?
Prior to its acquisition, key financial metrics for Amryt Pharma included revenue growth, particularly for Filsuvez and Lomitapide. Gross margin, operating expenses, and net income were also closely monitored to assess the company's profitability. Investors also paid attention to cash flow generation, as well as the company's debt levels and capital structure.
What are the key factors to evaluate for AMRT?
American Mart Corporation (AMRT) holds an AI score of 46/100 (low). Amryt Pharma, prior to its acquisition, presented a compelling investment thesis centered on its focus on rare diseases with significant unmet medical needs. Not financial advice.
How frequently does AMRT data refresh on this page?
AMRT's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven AMRT's recent stock price performance?
American Mart Corporation (AMRT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on rare diseases with high unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- This dossier is based on publicly available information and historical data prior to Amryt Pharma's acquisition by Chiesi Farmaceutici S.p.A. in 2023. The information may not reflect the current status of the company's products and operations under Chiesi's ownership.